Nitrogen Containing Patents (Class 514/471)
-
Publication number: 20090311331Abstract: The present invention provides a pellet formulation comprising colloidal silicon dioxide (CSD) and one or both of a surfactant and a plasticiser. A process for the production of 5 said formulation is also provided.Type: ApplicationFiled: June 28, 2007Publication date: December 17, 2009Inventor: Gisela Fridrun Podczeck
-
Publication number: 20090298899Abstract: The disclosure provides EP2 receptor agonist compounds and methods for using the compounds for treating conditions which can be alleviated by agonism of an EP2 receptor.Type: ApplicationFiled: December 30, 2008Publication date: December 3, 2009Inventors: Alexander William Oxford, Richard Jon Davis, Robert Alexander Coleman, Kenneth Lyle Clark, David Edward Clark, Neil Victor Harris, Garry Fenton, George Hynd, Keith Alfred James Stuttle, Jonathan Mark Sutton, Mark Richard Ashton, Edward Andrew Boyd, Shirley Ann Brunton
-
Publication number: 20090298934Abstract: The instant invention is directed towards compounds, including diamidines, that inhibit Tdp1 and are useful in the treatment and/or prevention of cancer and parasitic disease.Type: ApplicationFiled: March 27, 2007Publication date: December 3, 2009Applicant: GOVERNMENT OF THE US, AS REPRESENTED BY THE SECRETInventors: Yves Pommier, Christophe Marchand
-
Publication number: 20090298887Abstract: The present invention is directed to a method for improving the quality of seeds harvested from seed-producing plants. The method comprises treating the pre-planted seeds of the seed-producing plants with a seed treatment insecticide and treating the resulting plant with foliar applications of a foliar insecticide; or treating the pre-planted seeds of the seed-producing plants with a seed treatment insecticide; or treating seed-producing plants with foliar applications of a foliar insecticide.Type: ApplicationFiled: December 8, 2005Publication date: December 3, 2009Applicant: Syngenta Corp Protection, Inc.Inventor: Clifford Watrin
-
Patent number: 7625944Abstract: The present invention provides compounds that inhibit the activity of plasma kallikrein (PK) and methods of preventing and treating the formation of thrombin during or after a PK dependent disease or condition, for example, after fibrinolysis treatment.Type: GrantFiled: July 30, 2007Date of Patent: December 1, 2009Assignee: Activesite Pharmaceuticals, Inc.Inventors: Sukanto Sinha, Tamie Jo Chilcote
-
Publication number: 20090286862Abstract: The present invention relates to a preventive and/or therapeutic agent for psychoneurotic diseases, comprising an EP3 antagonist represented by the general formula (I): (wherein the meanings of characters are defined in the description). This compound has an antagonistic potency against EP3 and exhibits efficacy through unusual action mechanism as a preventive and/or therapeutic agent for psychoneurotic disorder, psychosomatic disorder, anxiety disorder, depression and disorder caused by stress.Type: ApplicationFiled: August 5, 2005Publication date: November 19, 2009Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Masami Narita, Kazutoyo Sato
-
Publication number: 20090275651Abstract: Compounds of the general formula (formula I) in which the meanings of the substituents R1 to R6 are as indicated in claim 1, have renin-inhibiting properties and can be used as medicines.Type: ApplicationFiled: September 14, 2006Publication date: November 5, 2009Inventors: Peter Herold, Robert Mah, Vincenzo Tschinke, Stefan Stutz, Aleksandar Stojanovic, Stjepan Jelakovic, Christiane Marti
-
Publication number: 20090258912Abstract: A compound of general formula (I): A process for preparing this compound. A fungicidal composition comprising a compound of general formula (I). A method for treating plants by applying a compound of general formula (I) or a composition comprising it.Type: ApplicationFiled: November 21, 2006Publication date: October 15, 2009Inventors: Pierre-Yves Coqueron, Darren James Mansfield, Philippe Desbordes, Heiko Rieck, Pierre Genix, Alain Villier, Marie-Claire Grosjean-Cournoyer
-
Patent number: 7601362Abstract: An effective gelled poison bait is provided for the control of such objective insect as cockroaches, wherein the bait comprises 1-methyl-2-nitro-3-[(tetrahydrofuryl)methyl]guanidine, carrageenan, polyvinyl alcohol, at least one selected from fats and fatty oils and water.Type: GrantFiled: June 14, 2004Date of Patent: October 13, 2009Assignee: Sumitomo Chemical Company, LimitedInventors: Satoshi Sembo, Kenya Okada
-
Publication number: 20090253656Abstract: The present invention is directed to a breast cancer resistance protein (BCRP/ABCG2) inhibitor. The BCRP inhibitor contains, as an active ingredient, an acrylonitrile derivative represented by formula (1): wherein one of R1 and R2 represents a cyano group and the other represents a hydrogen atom; Ar1 represents a group selected from among the groups represented by formulas (2) to (4): and Ar2 represents an aromatic hydrocarbon group having a condensed ring which may be substituted by a halogen atom, or a group selected from among the groups represented by the following formulas (5) to (15): or a salt thereof.Type: ApplicationFiled: March 29, 2006Publication date: October 8, 2009Applicant: Kabushiki Kaisha Yakult HonshaInventors: Ryuta Yamazaki, Yukiko Nishiyama, Tomio Furuta, Takeshi Matsuzaki, Hiroshi Hatano, Oh Yoshida, Masato Nagaoka, Ritsuo Aiyama, Shusuke Hashimoto, Yoshikazu Sugimoto
-
Publication number: 20090253684Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, COPD.Type: ApplicationFiled: December 2, 2008Publication date: October 8, 2009Inventors: Romyr Dominique, Robert Alan Goodnow, JR., Agnieszka Kowalczyk, Qi Qiao, Achyutharao Sidduri, Jefferson Wright Tilley
-
Publication number: 20090252704Abstract: The invention relates to a combination comprising an amount of an NO donor, such as ISDN, and/or an amount of another pharmaceutical agent that enhances neurotransmission or which acts as neuroprotectants such as memantine, clomethiazole and tacrine. These compositions can be used in producing cognition and learning enhancement, whereby the invention also provides for a new method of treatment of Alzheimer's disease and related neurodegenerative disorders.Type: ApplicationFiled: January 14, 2009Publication date: October 8, 2009Inventors: Allan M. GREEN, Robert Bender
-
Publication number: 20090233970Abstract: The present invention is directed to co-administration of a non-steroidal anti-inflammatory agent (NSAID) and acid blocking agent for the treatment of pain and inflammation with reduced gastrointestinal irritation. A pharmaceutical composition suitable for the co-administration contains a therapeutically effective amount of at least one non-steroidal anti-inflammatory agent, and a therapeutically effective amount of at least one acid blocking agent. A ratio of the non-steroidal anti-inflammatory agent to acid blocking agent in the composition is within a range that provides greater pain relief and reduction of inflammation with less gastrointestinal irritation than that obtainable by the administration of the non-steroidal anti-inflammatory agent or acid blocking agent alone. Examples of pharmaceutical compositions for co-administration of the agents are those containing ibuprofen and ranitidine (“ibudine”), as well as naproxen and ranitidine (“naprodine”).Type: ApplicationFiled: March 11, 2008Publication date: September 17, 2009Inventor: ROBERT P. NICKELL
-
Patent number: 7589111Abstract: A taxane having a cyclopentyl ester substituent at C10, a keto substituent at C9, a hydroxy substituent at C2, a 2-thienyl substituent at C3? and an isopropoxycarbamate substituent at C3?.Type: GrantFiled: February 14, 2005Date of Patent: September 15, 2009Assignee: Florida State University Research Foundation, Inc.Inventors: Robert A. Holton, Phong Vu
-
Patent number: 7589089Abstract: The present invention relates to compounds of formula I wherein R1, R2, R3, R4, and X are as defined herein or to pharmaceutically acceptable acid addition salts thereof, with the exception of 4-methoxy-N-[2-oxo-2-(phenylamino)ethyl]-N-phenyl-benzamide, 4-chloro-N-[2-[(4-methylphenyl)amino]-2-oxoethyl]-N-phenyl-benzamide, 4-chloro-N-[2-[5-chloro-2-methoxyphenyl)amino]-2-oxoethyl]-N-benzamide, 4-methyl-N-(2-oxo-2-[(2,4,6-trichlorophenyl)amino]ethyl]-N-benzamide, N-[2-[(4-methylphenyl)amino]-2-oxoethyl]-N-phenyl-benzamide, 4-methyl-N-[2-[(4-methylphenyl)amino]-2-oxoethyl]-N-phenyl-benzamide, 4-chloro-N-(2-oxo-2-[(2,4,6-trichlorophenyl)amino]ethyl]-N-benzamide and N-[2-[(2,4-dimethoxyphenyl)amino]-2-oxoethyl]-N-[(2-fluorophenyl)methyl]-benzeneacetamide. The compounds are useful in the treatment of neurological and neuropsychiatric disorders.Type: GrantFiled: August 23, 2007Date of Patent: September 15, 2009Assignee: Hoffmann-La Roche Inc.Inventors: Synese Jolidon, Robert Narquizian, Emmanuel Pinard
-
Publication number: 20090221569Abstract: The invention relates to methods of treatment or prophylaxis of physiological and/or pathological conditions with at least one LHRH antagonist, in particular at least one peptidomimetic LHRH antagonistsuch that the at least one LHRH antagonist is administered in a dose, which does not cause chemical (hormonal) castration.Type: ApplicationFiled: February 27, 2009Publication date: September 3, 2009Applicant: AETERNA ZENTARIS GmbHInventor: Juergen ENGEL
-
Publication number: 20090215730Abstract: Chemical compounds derived by in silico molecular modelling, having a well defined structure suitable for the blocking of the phosphorylation event, through the specific interaction of the chemical with the Casein Kinase 2 enzyme substrate phosphorylation domain or it's neighbourhood. This invention comprises also the pharmaceutical compositions containing such compounds, and their use in the preparation of medicines or agents for the treatment of diseases or conditions related with neoplasic processes.Type: ApplicationFiled: May 5, 2006Publication date: August 27, 2009Inventors: Rolando Eduardo Rodriguez Fernandez, Roberto Vera Alvarez, Ania De La Nuez Veulens, Yuliet Mazola Reyes, Silvio Ernesto Perea Rodriguez, Boris Ernesto Acevedo Castro, Alexis Musacchio Lasa, Raimundo Ubieta Gomez
-
Publication number: 20090214452Abstract: The invention is directed to a strategy for providing therapeutic or cosmetic benefit to skin by topically applying arginine chemically bound to a second (non-oligo arginine) compound in order to increase transepithelial delivery of arginine through a combination of increased solubility and flux across the skin. The arginine heteromers of the invention can add other complementary or beneficial properties for the skin beyond those that are arginine-related.Type: ApplicationFiled: December 28, 2006Publication date: August 27, 2009Inventor: Jacob M. Waugh
-
Publication number: 20090202630Abstract: The present invention is directed to pharmaceutical compositions comprising taste-masked microcapsules comprising ranitidine, orally disintegrating tablets comprising such compositions, and methods of making the pharmaceutical compositions and dosage forms of the present invention. The present invention is also directed to methods of administering the pharmaceutical compositions and orally disintegrating tablets to treat or prevent gastrointestinal disorders.Type: ApplicationFiled: February 13, 2009Publication date: August 13, 2009Inventors: Gopi Venkatesh, Craig Kramer, Julius Dave King, JR., Bennie L. Young
-
Publication number: 20090191129Abstract: This invention relates to novel compounds suitable for labelling or already labelled by 18F, methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by positron emission tomography (PET).Type: ApplicationFiled: October 23, 2008Publication date: July 30, 2009Inventors: Lutz LEHMANN, Andrea Thiele, Tobias Heinrich, Thomas Brumby, Christer Halldin, Balazs Gulyas, Sangram Nag
-
Publication number: 20090192172Abstract: Novel 2-alkylcycloalk(en)ylcarboxamides of the formula (I) in which X, s, R1, L, R2 and A are as defined in the description, a plurality of processes for preparing these compounds and their use for controlling unwanted microorganisms, and also novel intermediates and their preparation.Type: ApplicationFiled: December 8, 2005Publication date: July 30, 2009Applicant: Bayer Cropscience AGInventors: Ralf Dunkel, Hans-Ludwig Elbe, Jörg Nico Greul, Benoit Hartmann, Herbert Gayer, Thomas Seitz, Ulrike Wachendorff-Neumann, Peter Dahmen, Karl-Heinz Kuck
-
Publication number: 20090176786Abstract: The present invention relates to a benzoylurea compound represented by formula (I): wherein, X and Y represent a fluorine atom or a chlorine atom, R1 represents a lower alkyl group or the like, R2 represents a lower alkyl group, R3 represents a halogen atom or the like, R4 represents an alkylthio group optionally substituted with one or more of halogen atoms, or a salt thereof, and use thereof for controlling pests and the like.Type: ApplicationFiled: October 16, 2006Publication date: July 9, 2009Inventors: Masato Konobe, Shigeyuki Itoh, Norihisa Sakamoto, Araki Tomohiro, Yoshitomo Tohyama
-
Publication number: 20090170842Abstract: A pharmaceutical composition for use in treating, inhibiting, and/or preventing breast and/or ovarian cancer can include: a molecule having a structure of one of Compounds 1-38, pharmaceutically acceptable salt thereof, or analog thereof, and a pharmaceutically acceptable carrier containing the compound. The pharmaceutically acceptable carrier can be configured for oral, systemic, transdermal, intranasal, suppository, parenteral, intramuscular, intravenous, or subcutaneous administration. The compound can be present in the composition in a therapeutically effective amount for treating, inhibiting, and/or preventing breast and/or ovarian cancer. Also, the compound can be present in a therapeutically effective amount for enhancing production of BRCA1.Type: ApplicationFiled: November 13, 2008Publication date: July 2, 2009Applicant: University of KansasInventors: Roy A. Jensen, Lisa M. Harlan-Williams, Frank J. Schoenen, Jeffrey Aube, Gerald H. Lushington
-
Publication number: 20090156399Abstract: The invention relates to insecticidal mixtures comprising novaluron and at least one further known active compound from the group of the neonicotinoids, and to the use of these mixtures for controlling animal pests.Type: ApplicationFiled: August 3, 2006Publication date: June 18, 2009Applicant: Bayer CropScience AGInventors: Heike Hungenberg, Wolfgang Thielert, Peter-Wilhelm Krohn, Andreas Hinterhuber
-
Patent number: 7547716Abstract: A medicament for enhancing an effect of a cancer therapy based on a mode of action of DNA injury, which comprises as an active ingredient a compound represented by the general formula (I) or a physiologically acceptable salt thereof: wherein R represents an aryl-substituted alkyl group, an heteroaryl-substituted alkyl group, a cycloalkyl-substituted alkyl group, or a cyclic hydrocarbon group wherein said cyclic hydrocarbon group may be saturated, partly saturated, or aromatic; or Z may bind to R to form a cyclic structure, Z represents a hydrogen atom or a C1 to C6 alkyl group. The medicament enhanced the effect of the cancer therapy and decreases a dose of an anticancer agent and/or radiation, and therefore, can reduce side effects resulting from the cancer therapy.Type: GrantFiled: June 7, 2002Date of Patent: June 16, 2009Assignee: Institute of Medicinal Molecular Design, Inc.Inventors: Susumu Muto, Masayuki Komukai, Akiko Itai
-
Publication number: 20090149496Abstract: The invention relates to the use of Kv1.5 inhibitors for the therapy or prophylaxis of respiratory disorders, sleep-related respiratory disorders, central and obstructive sleep apneas, upper airway resistance syndrome, Cheyne-Stokes respiration, snoring, disrupted central respiratory drive, sudden child death, postoperative hypoxia and apnea, muscle-related respiratory disorders, respiratory disorders after long-term ventilation, respiratory disorders during adaptation in high mountains, acute and chronic lung disorders with hypoxia and hypercapnia, neurodegenerative disorders, dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, cancer disorders, breast cancer, lung cancer, colon cancer and prostate cancer.Type: ApplicationFiled: October 16, 2008Publication date: June 11, 2009Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBHInventors: Joachim BRENDEL, Heinz GOEGELEIN, Klaus WIRTH, Walter KAMM
-
Publication number: 20090143437Abstract: Compounds of formula (X): wherein: R2 is H or an optionally substituted C1-4 alkyl group; Y is either —(CH2)n—X—, where n is 1 or 2 and X is O, S, S(?O), S(?O)2, or NRN1, where RN1 is selected from H or optionally substituted C1-4 alkyl, or Y is —C(?O)NRN2—, where RN2 is selected from H, and optionally substituted C1-7 alkyl or C5-20 aryl; R3 is an optionally substituted C6 aryl group linked to a further optionally substituted C6 aryl group, wherein if both C6 aryl groups are benzene rings, there may be an oxygen bridge between the two rings, bound adjacent the link on both rings; A is a single bond or a C1-3 alkylene group; and R5 is either: (i) carboxy; (ii) a group of formula (II): or (iii) a group of formula (III): wherein R is optionally substituted C1-7 alkyl, C5-20 aryl or NRN3RN4, where RN3 and RN4 are independently selected from optionally substituted alkyl; (iv) tetrazol-5-yl.Type: ApplicationFiled: January 28, 2009Publication date: June 4, 2009Applicant: ASTERAND UK LIMITEDInventors: Alexander W. Oxford, Richard J. Davis, Robert A. Coleman, Kenneth L. Clark, David E. Clark, Neil V. Harris, Garry Fenton, George Hynd, Keith A.J. Stuttle, Jonathan M. Sutton, Christopher G. Newton
-
Publication number: 20090137611Abstract: The present invention relates to N-cyclopropyl-sulfonylamide derivatives of formula (I) wherein the substituents are cyclic groups, their process of preparation, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions: (I)Type: ApplicationFiled: April 5, 2007Publication date: May 28, 2009Inventors: Hans-Georg Schwarz, Sandra Gassmann, Karl-Heinz Kuck, Peter Dahmen, Ulrike Wachendorff-Neumann, Stephane Carbonne, Stephanie Gary, Christopher Steele, Alain Villier, Jean-Pierre Vors
-
Patent number: 7534768Abstract: The synergistic combination of a loop diuretic and a cardiac glycoside is useful in the treatment of DNA viral infections.Type: GrantFiled: December 17, 2004Date of Patent: May 19, 2009Assignee: Henderson Morely Research and Development Ltd.Inventor: Christopher Edward Hartley
-
Publication number: 20090124669Abstract: Novel compounds for the prevention and treatment of dermatological disorders with an immunoallergic, hyperproliferative and inflammatory component, and a method of producing such compounds. The compounds are bioisosteres of substances with avenanthramide structures.Type: ApplicationFiled: February 21, 2006Publication date: May 14, 2009Inventor: Carlo Ghisalberti
-
Publication number: 20090118268Abstract: This invention relates to the use of a group of aryl ureas in treating p38 mediated diseases, and pharmaceutical compositions for use in such therapy.Type: ApplicationFiled: October 10, 2008Publication date: May 7, 2009Inventors: Bernd Riedl, Jacques Dumas, Uday Khire, Timothy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood, Mary-Katherine Monahan, Reina Natero, Joel Renick, Robert N. Sibley
-
Patent number: 7528157Abstract: Compounds of formula (I): wherein: R2 is H or an optionally substituted C1-4 alkyl group; Y is either —(CH2)n—X—, where n is 1 or 2 and X is O, S, S(?O), S(?O)2, or NRN1, where RN1 is selected from H or optionally substituted C1-4 alkyl, or Y is —C(?O)NRN2—, where RN2 is selected from H, and optionally substituted C1-7 alkyl or C5-20 aryl; R3 is an optionally substituted C6 aryl group linked to a further optionally substituted C6 aryl group, wherein if both C6 aryl groups are benzene rings, there may be an oxygen bridge between the two rings, bound adjacent the link on both rings; A is a single bond or a C1-3 alkylene group; and R5 is either: (i) carboxy; (ii) a group of formula (II): (iii) a group of formula (III): wherein R is optionally substituted C1-7 alkyl, C5-20 aryl or NRN3RN4, where RN3 and RN4 are independently selected from optionally substituted C1-4 alkyl; (iv) tetrazol-5-yl.Type: GrantFiled: December 22, 2006Date of Patent: May 5, 2009Assignee: Asterand UK LimitedInventors: Alexander W. Oxford, Richard J. Davis, Robert A. Coleman, Kenneth L. Clark, David E. Clark, Neil V. Harris, Garry Fenton, George Hynd, Keith A. J. Stuttle, Jonathan M. Sutton, Christopher G. Newton
-
Publication number: 20090111698Abstract: Treatment with N-(2-phenylethyl)succinamic acid or its salts protects against inhibition of growth by a neonicotinoid compound applied as a seed treatment or applied directly on or near the root zone of the seedling.Type: ApplicationFiled: October 24, 2008Publication date: April 30, 2009Inventors: Franklin Paul Silverman, Dale O. Wilson, JR., Jennifer C. Kochan, Nicole Higgs, Peter D. Petracek, Prem Warrior, Karen S. Arthur
-
Patent number: 7524869Abstract: Taxanes having an ester substituent at C(10), a hydroxy substituent at C(7), and a range of C(2), C(9), C(14), and side chain substituents.Type: GrantFiled: October 1, 2003Date of Patent: April 28, 2009Assignee: Florida State University Research Foundation, Inc.Inventor: Robert A. Holton
-
Publication number: 20090105235Abstract: The present invention relates to increasing the activity of crop protection compositions comprising inhibitors of the nicotinic acetylcholine receptor (for example neonicotinoids) through the addition of ammonium salts and/or phosphonium salts or through the addition of ammonium or phosphonium salts and penetrants, to the corresponding compositions, to processes for preparing them and to their use in crop protection.Type: ApplicationFiled: November 30, 2006Publication date: April 23, 2009Applicant: Bayer CropScience AGInventors: Peter Jeschke, Ralf Nauen, Rolf Pontzen, Udo Reckmann, Peter Marczok, Reiner Fischer, Robert Velten, Christian Arnold, Erich Sanwald
-
Publication number: 20090105187Abstract: The present invention provides methods of identifying agents that reduce a level of active APOBEC3C in a cell. The present invention provides agents that reduce a level of active APOBEC3C in a cell; and compositions comprising the agents. The present invention further provides methods of reducing the mutation rate of a lentivirus in a cell; and methods of reducing the emergence of drug-resistant strains of lentivirus. The present invention further provides methods for treating lentivirus infections.Type: ApplicationFiled: October 31, 2005Publication date: April 23, 2009Inventors: Robert M. Grant, Khaoula Bourara
-
Publication number: 20090105257Abstract: The present invention relates generally to novel therapeutic compounds and more particularly to novel compounds, their use as GPR40 agonists, processes for their manufacture, and intermediates useful in their preparation.Type: ApplicationFiled: November 15, 2004Publication date: April 23, 2009Inventors: David Francis Corbett, Kate Anna Dwornik, Dulce Maria Garrido, Stephen Carl McKeown, Wendy Yoon Mills, Andrew James Peat, Terrence Lee Smalley, JR.
-
Publication number: 20090105218Abstract: Compounds of formula (I) are useful in the treatment of disease responsive to modulation of CRTH2 receptor activity, wherein: A represents a carboxyl group —COOH, or a carboxyl bioisostere; L1 is a bond, —CH2—, —OCH2—, —CH2CH2— or —CH?CH—; L2 is CONH—, —NHCO—, SO2NR1—, —NR1SO2 wherein R1 is hydrogen or C1-C3 alkyl, or a divalent radical of formula (X) or (Y), wherein ring Q is a non aromatic heterocyclic ring containing 5 to 7 ring atoms, including the nitrogen shown; L3 is a divalent linker radical of formula -(Alk1)m-(Z)n-(Alk2)p as defined in the description; ring Ar1 is an optionally substituted divalent phenyl radical or divalent 5- or 6-membered monocyclic heteroaryl radical, in which L1 and the H[B]sL3L2Ar2CONH-radical are linked to adjacent ring carbon atoms; ring Ar2 is an optionally substituted 1,3-phenylene radical, or an optionally substituted divalent 5- or 6-membered monocyclic heteroaryl radical, in which AL1Ar1NHCO-radical and the H[B]sL3L2-radical are linked to ring carbon atoms which are notType: ApplicationFiled: May 30, 2005Publication date: April 23, 2009Applicant: 7TM PHARMA A/SInventors: Trond Ulven, Thomas Frimurer, Oystein Rist, Evi Kostenis, Thomas Hogberg
-
Publication number: 20090105280Abstract: Pharmaceutical compositions comprising at least one compound of e.g. the formulas (Ie) and a pharmaceutically acceptable carrier which is useful in a medicine wherein the symbols and substituents have the following meaning —X— is e.g. and Y is e.g. or the pharmaceutically acceptable salts, esters or amides and prodrugs of the above identified compounds can be applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.Type: ApplicationFiled: September 20, 2006Publication date: April 23, 2009Applicant: REVOTAR BIOPHARMACEUTICALS AGInventors: Ewald M. Aydt, Remo Kranich
-
Publication number: 20090099154Abstract: Pharmaceutical sustained release composition comprising at least one active agent(s), or its tautomeric forms, analogues, isomers, polymorphs, solvates, or salts thereof; preferably an antiviral active agent is provided. Also provided is a process of preparation of such composition and method of using them. The sustained release compositions of the present invention are able to deliver the active agent in a desired manner for an extended period of time.Type: ApplicationFiled: June 29, 2006Publication date: April 16, 2009Applicant: PANACEA BIOTEC LTD.Inventors: Rajesh Jain, Kour Chand Jindal, Sukhjeet Singh, Sanjay Boldhane
-
Publication number: 20090093415Abstract: [Problem]To provide a therapeutic agent for irritable bowel syndrome (IBS), which is excellent in efficacy and safety. [Means for Resolution]It was shown that the bombesin 2 (BB2) receptor antagonists typified by RC-3095 are therapeutic agents for irritable bowel syndrome (IBS), which show excellent efficacy in both of an abdominal symptom and bowel movement disorder. Thus, according to the present invention, it became possible to provide a therapeutic agent for irritable bowel syndrome (IBS) which comprises, as an active ingredient, a bombesin 2 (BB2) receptor antagonist exerting an excellent efficacy in both an abdominal symptom and bowel movement disorder.Type: ApplicationFiled: April 19, 2006Publication date: April 9, 2009Applicant: ASTELLAS PHARMA INC.Inventor: Mayumi Yamano
-
Publication number: 20090093364Abstract: A resin composition containing an agricultural chemical in which the release of an agricultural chemical active ingredient is controlled; a production method thereof; and an agricultural chemical formulation; in other words, an agricultural chemical-containing resin composition which is a composition containing an agricultural chemical active ingredient, a resin, and a fatty acid metal salt, and characterized in that the composition is either in a compatible state or forming a matrix; its production method; and an agricultural chemical formulation including at least one of the agricultural chemical-containing resin compositions; in addition to an agricultural chemical-containing resin composition which is a composition containing an agricultural chemical active ingredient, a (meth)acrylate based resin, and a release controlling agent, and characterized in that the composition is either in a compatible state or forming a matrix; its production method; and an agricultural chemical formulation including at leastType: ApplicationFiled: February 2, 2007Publication date: April 9, 2009Inventors: Yoshihisa Endo, Satoru Yamamura, Yuichi Maekawa
-
Patent number: 7514452Abstract: The present invention provides 2-furancarboxylic acid hydrazide compounds represented by General Formula (I) below, and prodrugs, physiologically acceptable salts, hydrates, solvates thereof: wherein A is a group represented by Formula (a) or the like: (wherein either R4 or R5 represents cyano, nitro or the like, and the other represents a hydrogen atom or the like); either R1 or R2 represents a group: -D-(X)m-R6 or the like, and the other represents a group: -E-(Y)n-R7, hydrogen atom, aryl or the like; R3 is a hydrogen atom or the like; D and E independently represent aryl; X and Y independently represent O or the like; R6 and R7 independently represent alkyl, aryl, arylalkyl or the like; and m and n are independently 0 or 1, provided that the aryl is optionally substituted.Type: GrantFiled: January 30, 2003Date of Patent: April 7, 2009Assignee: Dainippon Pharmaceutical Co., LtdInventors: Akihito Fujii, Toshiyuki Negoro, Chiaki Migihashi, Makoto Murata, Keiji Nakamura, Takashi Nukuda, Takafumi Matsumoto, Kiyomi Imano
-
Publication number: 20090088438Abstract: Compounds of general formula I, and the salts and solvates thereof, wherein R1 represents the radical 2-benzoylphenylamino; R2 represents —(CH2)s—N(COR3)-A-J-T or —(CH2)s—N(R4)-B-J-T; and s, R3, R4, A, B, J and T have the meanings disclosed herein. These compounds are PPAR? modulators and, therefore, are useful for the treatment or prevention of a condition or a disease mediated by these receptors.Type: ApplicationFiled: June 25, 2008Publication date: April 2, 2009Applicant: LABORATORIOS SALVAT, S.A.Inventors: Carmen SERRA COMAS, Anna FERNANDEZ SERRAT, Dolors BALSA LOPEZ, Isabel MASIP MASIP, Juan Lorenzo CATENA RUIZ, Jose HIDALGO RODRIGUEZ, Carmen LAGUNAS ARNAL, Carolina SALCEDO ROCA, Andres FERNANDEZ GARCIA
-
Patent number: 7507754Abstract: Compounds of formula (I): wherein: R2 is H or an optionally substituted C1-4 alkyl group; Y is either —(CH2)n—X—, where n is 1 or 2 and X is O, S, S(?O), S(?O)2, or NRN1, where RN1 is selected from H or optionally substituted C1-4 alkyl, or Y is —C(?O)NRN2—, where RN2 is selected from H, and optionally substituted C1-7 alkyl or C5-20 aryl; R3 is an optionally substituted C6 aryl group linked to a further optionally substituted C6 aryl group, wherein if both C6 aryl groups are benzene rings, there may be an oxygen bridge between the two rings, bound adjacent the link on both rings; A is a single bond or a C1-3 alkylene group; and R5 is either: (i) carboxy; (ii) a group of formula (II): (iii) a group of formula (III): wherein R is optionally substituted C1-7 alkyl, C5-20 aryl or NRN3RN4, where RN3 and RN4 are independently selected from optionally substituted C1-4 alkyl; (iv) tetrazol-5-yl.Type: GrantFiled: August 14, 2007Date of Patent: March 24, 2009Assignee: Asterand UK LimitedInventors: Alexander W. Oxford, Richard J. Davis, Robert A. Coleman, Kenneth L. Clark, David E. Clark, Neil V. Harris, Garry Fenton, George Hynd, Keith A. J. Stuttle, Jonathan M. Sutton, Christopher G. Newton
-
Publication number: 20090074845Abstract: A transdermal active principle delivery means comprises a skin adherent or otherwise skin-tolerant substrate applicable to a skin area affected by DNA virus, which substrate includes a composition for treating DNA comprising a transdermally effective carrier medium including at least one active principle selected from the group consisting of diuretic agents and/or cardiac glycoside agents.Type: ApplicationFiled: August 22, 2006Publication date: March 19, 2009Applicant: HENDERSON MORLEY PLCInventors: Ian Stuart Pardoe, Christopher Hartley
-
Publication number: 20090076114Abstract: The present invention relates to cis-1,2-substituted stilbene derivatives, or their pharmaceutically acceptable salts, glucosides or solvates, a pharmaceutical composition comprising the compound, and use of said compound for preparation of a drug for treatment and/or prevention of diabetes or improvement of diabetic complications.Type: ApplicationFiled: July 20, 2005Publication date: March 19, 2009Inventors: Zhiyun Kang, Zuze Wu, Zhuangrong Sun, Zhongxiong Tang
-
Publication number: 20090075819Abstract: The present invention relates to Indanyl- and Tetrahydronaphtyl-amino-thiourea compounds of formula I wherein the variables R1 to R4 are as in the description. The invention relates also to methods of combating or controlling insects, arachnids or nematodes, to methods for protecting growing plants from attack or infestation by insects, arachnids or nematodes, to methods for the protection of seeds from soil insects and of the seedlings' roots and shoots from soil and foliar insects and to methods for treating, controlling, preventing or protecting animals against infestation or infection.Type: ApplicationFiled: November 15, 2006Publication date: March 19, 2009Applicant: BASF SEInventors: Markus Kordes, Christopher Koradin, Deborah L. Culbertson
-
Publication number: 20090069183Abstract: A method for applying a fungicide to a tree, the method comprising applying an aqueous insecticide or plant growth regulator composition to the bark periderm of woody plants without mechanically penetrating or piercing the bark of the plant, the insecticide or a plant growth regulator composition including (a) an insecticide or a plant growth regulator; (b) an organosiloxane surfactant; and (c) water.Type: ApplicationFiled: November 17, 2008Publication date: March 12, 2009Inventor: William Stringfellow
-
Publication number: 20090060871Abstract: A method for reducing psychological opioid dependence includes selecting a patient addicted to an opioid and administering to the patient an opioid agonist-antagonist for at least 14 days, thereby reducing craving for the opioid in the patient. An opioid agonist-antagonist is administered in a patient needing an average adherence to a treatment protocol of at least 95 percent. A non-injectable formulation containing an agonist-antagonist also is disclosed.Type: ApplicationFiled: October 24, 2008Publication date: March 5, 2009Inventors: Michael Victor VORONKOV, Efim David NEZHINSKY, Levon Gevorkovich ISAKULYAN, Daria Alexandrovna OCHERET